SB
QNCX icon

Strategic Blueprint’s Quince Therapeutics QNCX Stock Holding History

Strategic Blueprint’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-61
Closed -$13.7K – 581
2023
Q3 		$13.7K Hold
61
– – ﹤0.01% 525
2023
Q2 		$18.4K Hold
61
– – ﹤0.01% 533
2023
Q1 		$19K Hold
61
– – ﹤0.01% 506
2022
Q4 		$7.78K Sell
61
-2
-3% -$334 ﹤0.01% 504
2022
Q3 		$17K Sell
63
-6
-9% -$2.29K ﹤0.01% 485
2022
Q2 		$31K Sell
69
-63
-48% -$44.5K ﹤0.01% 484
2022
Q1 		$163K Sell
132
-21
-14% -$28.6K 0.02% 486
2021
Q4 		$386K Buy
+153
New +$934K 0.05% 321

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Strategic Blueprint's QNCX Position: Q4 2023 in Review

Strategic Blueprint sold out of Quince Therapeutics (QNCX) in Q4 2023, closing a stake of 61 shares — an estimated $13.7K sold.

Strategic Blueprint first reported a position in QNCX in Q4 2021 and held it in 8 quarters. The position peaked at $386K in Q4 2021. 42 funds tracked by Wall St. Rank hold QNCX as of Q4 2023.

  • Strategic Blueprint reported no remaining Quince Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Strategic Blueprint sold 61 Quince Therapeutics shares in Q4 2023, an estimated $13.7K.
  • Strategic Blueprint first reported a position in Quince Therapeutics in Q4 2021 and held it in 8 quarters.
  • Strategic Blueprint's Quince Therapeutics position peaked at $386K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2023.

Based on Strategic Blueprint's 13F filing for Q4 2023, filed 25 Jan 2024.